Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 4/20 | 0.62 |
| ▸ | CSF1R | P07333 | 8/20 | 0.48 |
| ▸ | MTOR | P42345 | 3/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23589716 | 0.90 | NUDT1 (0.66) | NUDT1CSF1RMTORPDE4BJAK2 | |
| SCHEMBL23589834 | 0.86 | NUDT1 (0.60) | NUDT1CSF1RMTORPDE4BJAK2 | |
| SCHEMBL23589956 | 0.84 | NUDT1 (0.56) | NUDT1CSF1RMTOR | |
| SCHEMBL23575732 | 0.84 | CA2 (0.57) | PDE4B | |
| SCHEMBL23589919 | 0.83 | NUDT1 (0.57) | NUDT1CSF1RMTORPTK2 | |
| SCHEMBL23589853 | 0.82 | NUDT1 (0.56) | NUDT1CSF1RMTORPDE4BEGFR | |
| SCHEMBL23575416 | 0.82 | NUDT1 (0.84) | NUDT1CSF1RPDE4BEGFR | |
| SCHEMBL31673787 | 0.82 | CSF1R (0.64) | NUDT1CSF1RMTOR | |
| SCHEMBL23590058 | 0.82 | NUDT1 (0.56) | NUDT1CSF1RMTORPDE4BPTK2 | |
| SCHEMBL23575320 | 0.80 | NUDT1 (0.67) | NUDT1CSF1RMTORPDE4BEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | RBBP9, MTHFD1, BRWD1 | NUDT1 823/4885CSF1R 3115/4885MTOR 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.